Our Team

Brandon Chow

Partner

+852 2151 5157

brandonchow@tongshang.com

Brandon Chow is a partner of Eric Chow & Co. in Association with Commerce & Finance Law Offices.

Brandon’s practice focuses on equity capital market transactions including representing both issuers and underwriters in initial public offerings on the Hong Kong Stock Exchange. He has experience in a wide range of corporate and commercial matters, including public takeovers and pre-initial public offering investments. He regularly advises clients on corporate and securities laws, corporate governance and Hong Kong Stock Exchange compliance and regulatory matters. Brandon advises clients across a range of industries, and has a particular focus on the technology, healthcare and real estate sectors.

Prior to joining Eric Chow & Co. in Association with Commerce & Finance Law Offices in 2019, Brandon worked at a leading U.K. law firm in Hong Kong. Brandon was recognised as “Hong Kong Rising Stars” by Asian Legal Business 2023 and shortlisted as “Rising Star Lawyer of the Year” by China Law & Practice Awards 2022. Most recently, he is ranked as a “Rising Star Partner” by IFLR1000 for his exceptional performance in 2023.

  • Experience
  • Education
  • Admissions and Qualifications
  • Languages

  • CEB International Capital Corporation Limited (HKEx: 2453) as the sole sponsor and underwriter in the HK$125 million global offering and IPO of H-shares of Xi’an Kingfar Property Services Co., Ltd. (HKEx: 1354) on the Main Board of the Hong Kong Stock Exchange. Kingfar Property is a state-owned comprehensive city service and property management service provider in China.
  • China Everbright Capital Limited as the sole sponsor in the US$20.05 million global offering and IPO of H-shares of Tianjin Construction Development Group Co., Ltd. (HKEx: 2515) on the Main Board of the Hong Kong Stock Exchange. Tianjin Construction Development Group Co., Ltd. is a construction group based in Tianjin which offers comprehensive construction services.
  • China Securities (International) Corporate Finance Company Limited and China Merchants Securities (HK) Co., Limited as the joint sponsors on the US$32.05 million global offering and IPO of H-shares of Pu’er Lancang Ancient Tea Co., Ltd. (HKEx: 6911) on the Main Board of the Hong Kong Stock Exchange. Pu’er Lancang Ancient Tea Co., Ltd. is a comprehensive tea company that integrates research and development, production, and sales.
  • Concord Healthcare Group Co., Ltd. (HKEx: 2453) in its US$82.9 million global offering and IPO of H-shares on the Main Board of the Hong Kong Stock Exchange. Concord Healthcare Group Co., Ltd. is a PRC hi-tech enterprise committed to providing advanced multidisciplinary treatment technology for cancer, and currently focuses on utilizing modern advanced radiotherapy technology and carrying out cutting-edge treatment research on cancer.
  • Beijing Luzhu Biotechnology Co., Ltd. (HKEx: 2480) in its US$43 million global offering and IPO of H-shares on the Main Board of the Hong Kong Stock Exchange. Luzhu Biotech is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases.
  • Tomorrow Education Technology Limited in an acquisition of approximately 75% of the issued shares in CTEH INC. (HKEX: 1620), a listed company of the Main Board of the Hong Kong Stock Exchange, for HK$273 million and the subsequent mandatory unconditional general offer.
  • Inner Mongolia Fuyuan International Industrial (Group) Co. Ltd. to enter into the sale and purchase agreement with China Modern Dairy Holdings Ltd. (“Modern Farming”, HKEx: 1117.HK), Inner Mongolia Mengniu Dairy (Group) Co., Ltd. and others. Modern Farming acquired the entire equity interests in Fuyuan for RMB3.4 billion (approximately US$534 million).
  • CCB International and China Securities (International) as joint sponsors on the US$124 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange of E-Star Commercial Management Company Limited, a leading commercial property operational service provider in the Greater Bay Area.
  • Immunotech Biopharm Ltd., a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy, in its US$145 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.
  • WAG Workdsec Corporate Finance Ltd. as sole sponsor on the US$200 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange of Ganglong China Property Group Limited, an established property developer in the Yangtze River Delta Region focusing the development of properties predominantly for residential use mixed with accompanying ancillary facilities.
  • Transtech Optelecom Science Holdings in its transfer of listing from GEM to the Main Board of the Hong Kong Stock Exchange.
  • Maike Tube Industry Holdings Ltd., in connection with its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited and its global offering. The company manufactures and sells standard prefabricated pipe nipple products and steel pipe products in Jinan.
  • BNPP, CITIC, CLSA, ICBCI, CCBI and ABCI as underwriters on the global offering and listing of shares of China Education Group, a Chinese university operator, on the main board of Hong Kong Stock Exchange. China Education Group is the largest Chinese education company listed in Hong Kong.
  • YuanShengTai Dairy Farm, in its HK$3.88 billion initial public offering and listing on the Main Board of the Hong Kong Stock Exchange.
  • Haitong International Capital, as the sponsor in the HK$200 million initial public offering and listing on the Main Board of the Hong Kong Stock Exchange by China Zhongsheng Resources Holdings Limited.
  • Champion Dynasty on the takeover of the controlling interests in G-Prop (Holdings) Limited for approximately HK$424 million and the subsequent mandatory unconditional general offer.
University of Warwick, 2010, LL.B.
The Chinese University of Hong Kong, 2011, PCLL
Solicitor, Hong Kong SAR
English, Mandarin, Cantonese